-
-
-
-
-
-
-
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
-
-
-
-
-
-
-
BioCryst to acquire Astria Therapeutics for $920 million
-
-
-
-
-
-
-
RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'
-
-
-
-
-
-
-
BioCryst Appoints Steve Frank to Board of Directors
-
-
-
-
-
-
-
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
-
-
-
-
-
-
-
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

